To summarize the current understanding and mechanisms of MIAT.
Approach:
Comprehensive Review: The review systematically details MIAT's basic characteristics, summarizes key research advances, explores its role in cardiovascular and cerebrovascular diseases, and evaluates its potential as a biomarker and therapeutic target.
Key Findings:
MIAT is implicated in various diseases beyond myocardial infarction, including ischemic stroke, hepatocellular carcinoma, and diabetic retinopathy.
Genome-wide association studies link single nucleotide polymorphisms in MIAT to myocardial infarction incidence.
MIAT exhibits dynamic subcellular localization, influencing its role as a transcriptional regulator or competing endogenous RNA.
Interpretation:
The review integrates both cardiovascular and cerebrovascular pathologies and discusses newly identified mechanisms.
Limitations:
No clinical trials targeting MIAT have been registered to date.
Few reviews have summarized MIAT's roles in both cardiovascular and cerebrovascular diseases comprehensively.
Conclusion:
The review provides insights into MIAT's current research status and mechanisms.
Three of 23 patients experienced heart failure deterioration following medication withdrawal, while adverse drug events occurred only among patients who continued therapy.
